Immupharma PLC IMM live on Investor Meet Company platform 7 April

TIDMIMM

Immupharma PLC

06 April 2020

6 April 2020

ImmuPharma PLC

("ImmuPharma" or the "Company")

ImmuPharma to present live on 'Investor Meet Company' platform

Tuesday 7 April 2020 | 10.30am (BST)

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM), a specialist drug discovery and development company, is pleased to announce that Tim McCarthy, Chairman of ImmuPharma, will provide a live presentation relating to the recently announced (30/3/20) GBP1.5 million Subscription and update on the Company's R&D programmes, via the 'Investor Meet Company' platform. The live presentation will be held on Tuesday 7 April 2020 @ 10.30am (BST).

ImmuPharma is committed to ensuring ongoing communication and transparency for all elements of its shareholder base, so that its strategy and progress within its therapy programmes are clearly communicated and understood. To this end and in order to access and engage with existing and potential shareholders efficiently, ImmuPharma has adopted the Investor Meet Company communications platform.

Questions can be submitted pre-event at investors@immupharma.com or in real time during the presentation, via the "Ask a Question" function. ImmuPharma will address all submitted questions within the confines of information already disclosed to the market through regulatory notifications. Responses to the Q&A from the live presentation will be published at the earliest opportunity on the Investor Meet Company platform.

Investor feedback can also be submitted directly to management post the event to ensure the Company can understand the views of all elements of its shareholder base.

Investor Meet Company is a digital platform that provides individual investors the same direct access to management as Institutional Investors around company announcements. Through live, interactive presentations, as part of the investor roadshow, all investors can now have the same opportunity for two-way engagement regardless of the number of shares they own or where they are located so they can come to an informed decision about ImmuPharma.

Investors interested in hearing more about ImmuPharma can sign up for free to Investor Meet Company at: https://www.investormeetcompany.com/register and add to meet ImmuPharma PLC where they will then be alerted to the forthcoming live presentation.

 
 
   For further information please contact: 
    ImmuPharma PLC ( www.immupharma.com ) 
     Tim McCarthy, Chairman                        + 44 (0) 207 152 4080 
    Dimitri Dimitriou, Chief Executive Officer 
    Lisa Baderoon, Head of Investor Relations      + 44 (0) 7721 413496 
 
     SPARK Advisory Partners Limited (NOMAD) 
     Neil Baldwin                                   +44 (0) 203 36 8 8974 
 
     Stanford Capital Partners (Joint Broker) 
     Patrick Claridge, John Howes                   +44 (0) 203 815 8880 
 
     SI Capital (Joint Broker) 
     Nick Emerson                                   +44 (0) 1483 413500 
    4Reliance (Euronext Growth Listing Sponsor)    +32 (0) 2 747 02 60 
     Jean-Charles Snoy 
 
     Degroof Petercam (Liquidity Provider)          +32 (0) 2 287 95 34 
     Erik De Clippel 
 
     Backstage Communication 
     Olivier Duquaine                               +32 (0) 477 504 784 
     Jean-Louis Dubrule                             +32 (0) 497 50 84 03

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio consists of four novel peptide therapy areas which are: Autoimmunity, Metabolism, Cancer and Anti-Infectives. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 29 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor(TM) to fund a new international Phase III trial for Lupuzor(TM) and commercialise in the US. For additional information about ImmuPharma please visit www.immupharma.com. ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAFLFFVSAIVIII

(END) Dow Jones Newswires

April 06, 2020 02:00 ET (06:00 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2024 to Aug 2024